23andMe seeks second auction as ex-CEO outbids Regeneron
Source: SeekingAlpha
2025-06-05 07:13:35 ET
More on 23andMe, Regeneron Pharmaceuticals
- Itepekimab Failure A Setback For Sanofi And Regeneron
- Regeneron's 23andMe Steal - Smart Genetics Play That Won't Cure Near-Term Growth Pains
- Regeneron Pharmaceuticals, Inc. (REGN) RBC Capital Markets Global Healthcare Conference (Transcript)
- Regeneron reports early data in mid-stage trial of obesity treatment
- Notable analyst calls this week: Southwest Airlines, Regeneron and Nvidia among top picks
Read the full article on Seeking Alpha
For further details see:
23andMe seeks second auction as ex-CEO outbids Regeneron
Regeneron Pharmaceuticals Inc.
NASDAQ: REGN
REGN Trading
-1.59% G/L:
$742.885 Last:
150,713 Volume:
$754.55 Open:
REGN Latest News
March 12, 2026 04:04:00 am
In 2036, Investors Will Regret Not Loading Up on This Multibagger in the Making
REGN Stock Data
$80,621,924,056
100,116,656
N/A
714
N/A
Biotechnology & Life Sciences
Healthcare
US
Tarrytown
